#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=MicroRNAs ( miRNAs ) are a class of non-coding single-stranded RNA molecules encoded by endogenous genes of approximately 20 to 24 nucleotide ( nt ) in length .
3-1	17-26	MicroRNAs	abstract	new	coref	3-6[5_0]
3-2	27-28	(	_	_	_	_
3-3	29-35	miRNAs	abstract	new	coref	4-2
3-4	36-37	)	_	_	_	_
3-5	38-41	are	_	_	_	_
3-6	42-43	a	abstract[5]	giv[5]	_	_
3-7	44-49	class	abstract[5]	giv[5]	_	_
3-8	50-52	of	abstract[5]	giv[5]	_	_
3-9	53-63	non-coding	abstract[5]|object[7]	giv[5]|new[7]	_	_
3-10	64-79	single-stranded	abstract[5]|object[7]	giv[5]|new[7]	_	_
3-11	80-83	RNA	abstract[5]|substance|object[7]	giv[5]|new|new[7]	coref	6-20
3-12	84-93	molecules	abstract[5]|object[7]	giv[5]|new[7]	_	_
3-13	94-101	encoded	_	_	_	_
3-14	102-104	by	_	_	_	_
3-15	105-115	endogenous	abstract[8]	new[8]	_	_
3-16	116-121	genes	abstract[8]	new[8]	_	_
3-17	122-124	of	abstract[8]	new[8]	_	_
3-18	125-138	approximately	abstract[8]|quantity[9]	new[8]|new[9]	coref	9-14[0_9]
3-19	139-141	20	abstract[8]|quantity[9]	new[8]|new[9]	_	_
3-20	142-144	to	abstract[8]	new[8]	_	_
3-21	145-147	24	abstract[8]|quantity[10]	new[8]|new[10]	appos	3-24[0_10]
3-22	148-158	nucleotide	abstract[8]|quantity[10]	new[8]|new[10]	_	_
3-23	159-160	(	_	_	_	_
3-24	161-163	nt	quantity	giv	_	_
3-25	164-165	)	_	_	_	_
3-26	166-168	in	_	_	_	_
3-27	169-175	length	quantity	new	coref	9-19
3-28	176-177	.	_	_	_	_

#Text=Since miRNAs were first discovered in Caenorhabditis elegans , more and more miRNAs have been identified in humans , animals , plants and viruses .
4-1	178-183	Since	_	_	_	_
4-2	184-190	miRNAs	abstract	giv	coref	4-10[15_0]
4-3	191-195	were	_	_	_	_
4-4	196-201	first	_	_	_	_
4-5	202-212	discovered	_	_	_	_
4-6	213-215	in	_	_	_	_
4-7	216-230	Caenorhabditis	abstract	new	_	_
4-8	231-238	elegans	_	_	_	_
4-9	239-240	,	_	_	_	_
4-10	241-245	more	abstract[15]	giv[15]	coref	5-10[0_15]
4-11	246-249	and	abstract[15]	giv[15]	_	_
4-12	250-254	more	abstract[15]	giv[15]	_	_
4-13	255-261	miRNAs	abstract[15]	giv[15]	_	_
4-14	262-266	have	_	_	_	_
4-15	267-271	been	_	_	_	_
4-16	272-282	identified	_	_	_	_
4-17	283-285	in	_	_	_	_
4-18	286-292	humans	person	new	_	_
4-19	293-294	,	_	_	_	_
4-20	295-302	animals	animal	new	_	_
4-21	303-304	,	_	_	_	_
4-22	305-311	plants	plant	new	_	_
4-23	312-315	and	_	_	_	_
4-24	316-323	viruses	abstract	new	coref	16-1
4-25	324-325	.	_	_	_	_

#Text=With the advance in miRNA research , the way miRNAs are produced and function is well clarified .
5-1	326-330	With	_	_	_	_
5-2	331-334	the	abstract[20]	new[20]	_	_
5-3	335-342	advance	abstract[20]	new[20]	_	_
5-4	343-345	in	abstract[20]	new[20]	_	_
5-5	346-351	miRNA	abstract[20]|abstract|abstract[22]	new[20]|new|new[22]	coref|coref	6-4|6-4
5-6	352-360	research	abstract[20]|abstract[22]	new[20]|new[22]	_	_
5-7	361-362	,	_	_	_	_
5-8	363-366	the	abstract[23]	new[23]	_	_
5-9	367-370	way	abstract[23]	new[23]	_	_
5-10	371-377	miRNAs	abstract	giv	coref	14-31
5-11	378-381	are	_	_	_	_
5-12	382-390	produced	_	_	_	_
5-13	391-394	and	_	_	_	_
5-14	395-403	function	abstract	new	coref	15-18
5-15	404-406	is	_	_	_	_
5-16	407-411	well	_	_	_	_
5-17	412-421	clarified	_	_	_	_
5-18	422-423	.	_	_	_	_

#Text=The maturity of miRNA includes the following stages : First , the non-coding region of DNA is transcribed by RNA polymerase I to form a precursor transcript ( primary miRNA , pri-miRNA ) with a hat structure ( 7MGpppG ) and a poly(A ) tail .
6-1	424-427	The	abstract[26]	new[26]	_	_
6-2	428-436	maturity	abstract[26]	new[26]	_	_
6-3	437-439	of	abstract[26]	new[26]	_	_
6-4	440-445	miRNA	abstract[26]|place	new[26]|giv	coref	7-19
6-5	446-454	includes	_	_	_	_
6-6	455-458	the	abstract[28]	new[28]	_	_
6-7	459-468	following	abstract[28]	new[28]	_	_
6-8	469-475	stages	abstract[28]	new[28]	_	_
6-9	476-477	:	_	_	_	_
6-10	478-483	First	_	_	_	_
6-11	484-485	,	_	_	_	_
6-12	486-489	the	place[29]	new[29]	_	_
6-13	490-500	non-coding	place[29]	new[29]	_	_
6-14	501-507	region	place[29]	new[29]	_	_
6-15	508-510	of	place[29]	new[29]	_	_
6-16	511-514	DNA	place[29]|substance	new[29]|new	_	_
6-17	515-517	is	_	_	_	_
6-18	518-529	transcribed	_	_	_	_
6-19	530-532	by	_	_	_	_
6-20	533-536	RNA	substance	giv	_	_
6-21	537-547	polymerase	object	new	_	_
6-22	548-549	I	person	acc	_	_
6-23	550-552	to	_	_	_	_
6-24	553-557	form	_	_	_	_
6-25	558-559	a	abstract[34]	new[34]	appos	6-29[35_34]
6-26	560-569	precursor	abstract[34]	new[34]	_	_
6-27	570-580	transcript	abstract[34]	new[34]	_	_
6-28	581-582	(	_	_	_	_
6-29	583-590	primary	abstract[35]	giv[35]	_	_
6-30	591-596	miRNA	abstract[35]	giv[35]	_	_
6-31	597-598	,	_	_	_	_
6-32	599-608	pri-miRNA	abstract	new	coref	7-1[42_0]
6-33	609-610	)	_	_	_	_
6-34	611-615	with	_	_	_	_
6-35	616-617	a	abstract[38]	new[38]	appos	6-39[0_38]
6-36	618-621	hat	object|abstract[38]	new|new[38]	_	_
6-37	622-631	structure	abstract[38]	new[38]	_	_
6-38	632-633	(	_	_	_	_
6-39	634-641	7MGpppG	abstract	giv	coref	7-25[49_0]
6-40	642-643	)	_	_	_	_
6-41	644-647	and	_	_	_	_
6-42	648-649	a	animal[40]|object[41]	new[40]|new[41]	_	_
6-43	650-656	poly(A	animal[40]|object[41]	new[40]|new[41]	_	_
6-44	657-658	)	object[41]	new[41]	_	_
6-45	659-663	tail	object[41]	new[41]	_	_
6-46	664-665	.	_	_	_	_

#Text=The pri-miRNA is then subjected to cleavage by RNase III nuclease Drosha and cofactor Pasha to generate a miRNA precursor ( pre-miRNA ) with a hairpin structure of approximately 70 – 90 nt .
7-1	666-669	The	abstract[42]	giv[42]	_	_
7-2	670-679	pri-miRNA	abstract[42]	giv[42]	_	_
7-3	680-682	is	_	_	_	_
7-4	683-687	then	_	_	_	_
7-5	688-697	subjected	_	_	_	_
7-6	698-700	to	_	_	_	_
7-7	701-709	cleavage	event[43]	new[43]	_	_
7-8	710-712	by	event[43]	new[43]	_	_
7-9	713-718	RNase	event[43]	new[43]	_	_
7-10	719-722	III	_	_	_	_
7-11	723-731	nuclease	_	_	_	_
7-12	732-738	Drosha	_	_	_	_
7-13	739-742	and	_	_	_	_
7-14	743-751	cofactor	person	new	_	_
7-15	752-757	Pasha	_	_	_	_
7-16	758-760	to	_	_	_	_
7-17	761-769	generate	_	_	_	_
7-18	770-771	a	object[46]	new[46]	_	_
7-19	772-777	miRNA	abstract|object[46]	giv|new[46]	coref	9-10[57_0]
7-20	778-787	precursor	object[46]	new[46]	_	_
7-21	788-789	(	_	_	_	_
7-22	790-799	pre-miRNA	substance	new	coref	8-1
7-23	800-801	)	_	_	_	_
7-24	802-806	with	_	_	_	_
7-25	807-808	a	abstract[49]	giv[49]	_	_
7-26	809-816	hairpin	place|abstract[49]	new|giv[49]	_	_
7-27	817-826	structure	abstract[49]	giv[49]	_	_
7-28	827-829	of	abstract[49]	giv[49]	_	_
7-29	830-843	approximately	abstract[49]|quantity[51]	giv[49]|new[51]	_	_
7-30	844-846	70	abstract[49]|quantity[51]	giv[49]|new[51]	_	_
7-31	847-848	–	abstract[49]|quantity[51]	giv[49]|new[51]	_	_
7-32	849-851	90	abstract[49]|quantity|quantity[51]	giv[49]|new|new[51]	_	_
7-33	852-854	nt	abstract[49]|quantity[51]	giv[49]|new[51]	_	_
7-34	855-856	.	_	_	_	_

#Text=Pre-miRNA is exported to the cytoplasm by RanGTP-dependent exportin 5 .
8-1	857-866	Pre-miRNA	substance	giv	coref	9-3[56_0]
8-2	867-869	is	_	_	_	_
8-3	870-878	exported	_	_	_	_
8-4	879-881	to	_	_	_	_
8-5	882-885	the	place[53]	new[53]	coref	11-10[77_53]
8-6	886-895	cytoplasm	place[53]	new[53]	_	_
8-7	896-898	by	_	_	_	_
8-8	899-915	RanGTP-dependent	person|abstract[55]	new|new[55]	_	_
8-9	916-924	exportin	abstract[55]	new[55]	_	_
8-10	925-926	5	abstract[55]	new[55]	_	_
8-11	927-928	.	_	_	_	_

#Text=Subsequently , the pre-miRNA is hydrolyzed and digested into a double-stranded miRNA of 20 to 24 nt in length , which consists of a guide strand miRNA and an incompletely complementary passenger strand miRNA* .
9-1	929-941	Subsequently	_	_	_	_
9-2	942-943	,	_	_	_	_
9-3	944-947	the	substance[56]	giv[56]	_	_
9-4	948-957	pre-miRNA	substance[56]	giv[56]	_	_
9-5	958-960	is	_	_	_	_
9-6	961-971	hydrolyzed	_	_	_	_
9-7	972-975	and	_	_	_	_
9-8	976-984	digested	_	_	_	_
9-9	985-989	into	_	_	_	_
9-10	990-991	a	abstract[57]	giv[57]	coref	9-24[62_57]
9-11	992-1007	double-stranded	abstract[57]	giv[57]	_	_
9-12	1008-1013	miRNA	abstract[57]	giv[57]	_	_
9-13	1014-1016	of	abstract[57]	giv[57]	_	_
9-14	1017-1019	20	abstract[57]|quantity	giv[57]|giv	_	_
9-15	1020-1022	to	_	_	_	_
9-16	1023-1025	24	quantity[59]	new[59]	_	_
9-17	1026-1028	nt	quantity[59]	new[59]	_	_
9-18	1029-1031	in	quantity[59]	new[59]	_	_
9-19	1032-1038	length	quantity[59]|quantity	new[59]|giv	_	_
9-20	1039-1040	,	_	_	_	_
9-21	1041-1046	which	_	_	_	_
9-22	1047-1055	consists	_	_	_	_
9-23	1056-1058	of	_	_	_	_
9-24	1059-1060	a	place[61]|abstract[62]	new[61]|giv[62]	coref|coref|coref|coref	9-29[64_61]|10-8[0_62]|9-29[64_61]|10-8[0_62]
9-25	1061-1066	guide	place[61]|abstract[62]	new[61]|giv[62]	_	_
9-26	1067-1073	strand	place[61]|abstract[62]	new[61]|giv[62]	_	_
9-27	1074-1079	miRNA	abstract[62]	giv[62]	_	_
9-28	1080-1083	and	_	_	_	_
9-29	1084-1086	an	place[64]	giv[64]	coref	10-8[70_64]
9-30	1087-1099	incompletely	place[64]	giv[64]	_	_
9-31	1100-1113	complementary	place[64]	giv[64]	_	_
9-32	1114-1123	passenger	person|place[64]	new|giv[64]	_	_
9-33	1124-1130	strand	place[64]	giv[64]	_	_
9-34	1131-1137	miRNA*	place[64]	giv[64]	_	_
9-35	1138-1139	.	_	_	_	_

#Text=The duplex is unwounded by helicase and miRNA guide strand then combined with the RNA-induced silencing complex ( RISC ) to recognize the target gene .
10-1	1140-1143	The	object[65]	new[65]	_	_
10-2	1144-1150	duplex	object[65]	new[65]	_	_
10-3	1151-1153	is	_	_	_	_
10-4	1154-1163	unwounded	_	_	_	_
10-5	1164-1166	by	_	_	_	_
10-6	1167-1175	helicase	substance|animal[67]	new|new[67]	ana|ana	14-4[0_67]|14-4[0_67]
10-7	1176-1179	and	animal[67]	new[67]	_	_
10-8	1180-1185	miRNA	animal[67]|abstract|place[70]	new[67]|giv|giv[70]	coref|coref|coref|coref	11-1[75_70]|12-1[78_0]|11-1[75_70]|12-1[78_0]
10-9	1186-1191	guide	animal[67]|object|place[70]	new[67]|new|giv[70]	_	_
10-10	1192-1198	strand	animal[67]|place[70]	new[67]|giv[70]	_	_
10-11	1199-1203	then	_	_	_	_
10-12	1204-1212	combined	_	_	_	_
10-13	1213-1217	with	_	_	_	_
10-14	1218-1221	the	abstract[72]	new[72]	_	_
10-15	1222-1233	RNA-induced	abstract|abstract[72]	new|new[72]	_	_
10-16	1234-1243	silencing	abstract[72]	new[72]	_	_
10-17	1244-1251	complex	abstract[72]	new[72]	_	_
10-18	1252-1253	(	_	_	_	_
10-19	1254-1258	RISC	event	new	_	_
10-20	1259-1260	)	_	_	_	_
10-21	1261-1263	to	_	_	_	_
10-22	1264-1273	recognize	_	_	_	_
10-23	1274-1277	the	abstract[74]	new[74]	coref	12-5[79_74]
10-24	1278-1284	target	abstract[74]	new[74]	_	_
10-25	1285-1289	gene	abstract[74]	new[74]	_	_
10-26	1290-1291	.	_	_	_	_

#Text=The passenger strand miRNA* is usually rapidly degraded in the cytoplasm .
11-1	1292-1295	The	place[75]|abstract[76]	giv[75]|new[76]	_	_
11-2	1296-1305	passenger	place[75]|abstract[76]	giv[75]|new[76]	_	_
11-3	1306-1312	strand	place[75]|abstract[76]	giv[75]|new[76]	_	_
11-4	1313-1319	miRNA*	abstract[76]	new[76]	_	_
11-5	1320-1322	is	_	_	_	_
11-6	1323-1330	usually	_	_	_	_
11-7	1331-1338	rapidly	_	_	_	_
11-8	1339-1347	degraded	_	_	_	_
11-9	1348-1350	in	_	_	_	_
11-10	1351-1354	the	place[77]	giv[77]	_	_
11-11	1355-1364	cytoplasm	place[77]	giv[77]	_	_
11-12	1365-1366	.	_	_	_	_

#Text=The mature miRNA recognizes the target gene through the 3′UTR of the target gene mRNA .
12-1	1367-1370	The	abstract[78]	giv[78]	coref	13-2[83_78]
12-2	1371-1377	mature	abstract[78]	giv[78]	_	_
12-3	1378-1383	miRNA	abstract[78]	giv[78]	_	_
12-4	1384-1394	recognizes	_	_	_	_
12-5	1395-1398	the	abstract[79]	giv[79]	coref	12-14[0_79]
12-6	1399-1405	target	abstract[79]	giv[79]	_	_
12-7	1406-1410	gene	abstract[79]	giv[79]	_	_
12-8	1411-1418	through	_	_	_	_
12-9	1419-1422	the	abstract[80]	new[80]	_	_
12-10	1423-1428	3′UTR	abstract[80]	new[80]	_	_
12-11	1429-1431	of	abstract[80]	new[80]	_	_
12-12	1432-1435	the	abstract[80]	new[80]	_	_
12-13	1436-1442	target	abstract[80]	new[80]	_	_
12-14	1443-1447	gene	abstract|abstract[82]	giv|new[82]	coref|coref|coref|coref	13-9[84_82]|14-37|13-9[84_82]|14-37
12-15	1448-1452	mRNA	abstract[82]	new[82]	_	_
12-16	1453-1454	.	_	_	_	_

#Text=When the mature miRNA is fully complementary to the target mRNA , the target mRNA will be degraded .
13-1	1455-1459	When	_	_	_	_
13-2	1460-1463	the	abstract[83]	giv[83]	_	_
13-3	1464-1470	mature	abstract[83]	giv[83]	_	_
13-4	1471-1476	miRNA	abstract[83]	giv[83]	_	_
13-5	1477-1479	is	_	_	_	_
13-6	1480-1485	fully	_	_	_	_
13-7	1486-1499	complementary	_	_	_	_
13-8	1500-1502	to	_	_	_	_
13-9	1503-1506	the	abstract[84]	giv[84]	coref	13-13[85_84]
13-10	1507-1513	target	abstract[84]	giv[84]	_	_
13-11	1514-1518	mRNA	abstract[84]	giv[84]	_	_
13-12	1519-1520	,	_	_	_	_
13-13	1521-1524	the	abstract[85]	giv[85]	coref	14-14[89_85]
13-14	1525-1531	target	abstract[85]	giv[85]	_	_
13-15	1532-1536	mRNA	abstract[85]	giv[85]	_	_
13-16	1537-1541	will	_	_	_	_
13-17	1542-1544	be	_	_	_	_
13-18	1545-1553	degraded	_	_	_	_
13-19	1554-1555	.	_	_	_	_

#Text=However , if their sequences are not fully paired , the translation of the target mRNA will be inhibited and the integrity of the mRNA will not be affected . miRNAs have the broadest range of gene regulation and regulate a variety of biological processes , including early embryo development , cell proliferation and differentiation , apoptosis and death , viral infection and tumorigenesis .
14-1	1556-1563	However	_	_	_	_
14-2	1564-1565	,	_	_	_	_
14-3	1566-1568	if	_	_	_	_
14-4	1569-1574	their	animal|abstract[87]	giv|new[87]	_	_
14-5	1575-1584	sequences	abstract[87]	new[87]	_	_
14-6	1585-1588	are	_	_	_	_
14-7	1589-1592	not	_	_	_	_
14-8	1593-1598	fully	_	_	_	_
14-9	1599-1605	paired	_	_	_	_
14-10	1606-1607	,	_	_	_	_
14-11	1608-1611	the	event[88]	new[88]	_	_
14-12	1612-1623	translation	event[88]	new[88]	_	_
14-13	1624-1626	of	event[88]	new[88]	_	_
14-14	1627-1630	the	event[88]|abstract[89]	new[88]|giv[89]	coref	14-24[91_89]
14-15	1631-1637	target	event[88]|abstract[89]	new[88]|giv[89]	_	_
14-16	1638-1642	mRNA	event[88]|abstract[89]	new[88]|giv[89]	_	_
14-17	1643-1647	will	_	_	_	_
14-18	1648-1650	be	_	_	_	_
14-19	1651-1660	inhibited	_	_	_	_
14-20	1661-1664	and	_	_	_	_
14-21	1665-1668	the	abstract[90]	new[90]	_	_
14-22	1669-1678	integrity	abstract[90]	new[90]	_	_
14-23	1679-1681	of	abstract[90]	new[90]	_	_
14-24	1682-1685	the	abstract[90]|abstract[91]	new[90]|giv[91]	_	_
14-25	1686-1690	mRNA	abstract[90]|abstract[91]	new[90]|giv[91]	_	_
14-26	1691-1695	will	_	_	_	_
14-27	1696-1699	not	_	_	_	_
14-28	1700-1702	be	_	_	_	_
14-29	1703-1711	affected	_	_	_	_
14-30	1712-1713	.	_	_	_	_
14-31	1714-1720	miRNAs	abstract	giv	coref	18-6
14-32	1721-1725	have	_	_	_	_
14-33	1726-1729	the	abstract[93]	new[93]	_	_
14-34	1730-1738	broadest	abstract[93]	new[93]	_	_
14-35	1739-1744	range	abstract[93]	new[93]	_	_
14-36	1745-1747	of	abstract[93]	new[93]	_	_
14-37	1748-1752	gene	abstract[93]|abstract|abstract[95]	new[93]|giv|new[95]	_	_
14-38	1753-1763	regulation	abstract[93]|abstract[95]	new[93]|new[95]	_	_
14-39	1764-1767	and	_	_	_	_
14-40	1768-1776	regulate	_	_	_	_
14-41	1777-1778	a	abstract[96]	new[96]	_	_
14-42	1779-1786	variety	abstract[96]	new[96]	_	_
14-43	1787-1789	of	abstract[96]	new[96]	_	_
14-44	1790-1800	biological	abstract[96]|abstract[97]	new[96]|new[97]	_	_
14-45	1801-1810	processes	abstract[96]|abstract[97]	new[96]|new[97]	_	_
14-46	1811-1812	,	abstract[96]	new[96]	_	_
14-47	1813-1822	including	abstract[96]	new[96]	_	_
14-48	1823-1828	early	abstract[96]|event[99]	new[96]|new[99]	_	_
14-49	1829-1835	embryo	abstract[96]|substance|event[99]	new[96]|new|new[99]	_	_
14-50	1836-1847	development	abstract[96]|event[99]	new[96]|new[99]	_	_
14-51	1848-1849	,	abstract[96]	new[96]	_	_
14-52	1850-1854	cell	abstract[96]|place|event[101]	new[96]|new|new[101]	coref|coref|coref|coref	18-30|18-30[154_101]|18-30|18-30[154_101]
14-53	1855-1868	proliferation	abstract[96]|event[101]	new[96]|new[101]	_	_
14-54	1869-1872	and	abstract[96]	new[96]	_	_
14-55	1873-1888	differentiation	abstract[96]|event	new[96]|new	_	_
14-56	1889-1890	,	abstract[96]	new[96]	_	_
14-57	1891-1900	apoptosis	abstract[96]|event	new[96]|new	_	_
14-58	1901-1904	and	abstract[96]	new[96]	_	_
14-59	1905-1910	death	abstract[96]|event	new[96]|new	coref	17-11
14-60	1911-1912	,	abstract[96]	new[96]	_	_
14-61	1913-1918	viral	abstract[96]|object|event[106]	new[96]|new|new[106]	coref|coref	15-27[0_106]|15-27[0_106]
14-62	1919-1928	infection	abstract[96]|event[106]	new[96]|new[106]	_	_
14-63	1929-1932	and	abstract[96]	new[96]	_	_
14-64	1933-1946	tumorigenesis	abstract[96]|abstract	new[96]|new	coref	18-26
14-65	1947-1948	.	_	_	_	_

#Text=Avian immunosuppressive disease refers to a series of infectious diseases that result in damage or loss of function to the immune system of the poultry after infection .
15-1	1949-1954	Avian	abstract[108]	new[108]	coref	16-8[121_108]
15-2	1955-1972	immunosuppressive	abstract[108]	new[108]	_	_
15-3	1973-1980	disease	abstract[108]	new[108]	_	_
15-4	1981-1987	refers	_	_	_	_
15-5	1988-1990	to	_	_	_	_
15-6	1991-1992	a	abstract[109]	new[109]	_	_
15-7	1993-1999	series	abstract[109]	new[109]	_	_
15-8	2000-2002	of	abstract[109]	new[109]	_	_
15-9	2003-2013	infectious	abstract[109]|abstract[110]	new[109]|new[110]	coref	17-30[143_110]
15-10	2014-2022	diseases	abstract[109]|abstract[110]	new[109]|new[110]	_	_
15-11	2023-2027	that	_	_	_	_
15-12	2028-2034	result	_	_	_	_
15-13	2035-2037	in	_	_	_	_
15-14	2038-2044	damage	abstract	new	_	_
15-15	2045-2047	or	_	_	_	_
15-16	2048-2052	loss	abstract[112]	new[112]	_	_
15-17	2053-2055	of	abstract[112]	new[112]	_	_
15-18	2056-2064	function	abstract[112]|abstract	new[112]|giv	_	_
15-19	2065-2067	to	_	_	_	_
15-20	2068-2071	the	abstract[114]	new[114]	_	_
15-21	2072-2078	immune	abstract[114]	new[114]	_	_
15-22	2079-2085	system	abstract[114]	new[114]	_	_
15-23	2086-2088	of	abstract[114]	new[114]	_	_
15-24	2089-2092	the	abstract[114]|animal[115]	new[114]|new[115]	_	_
15-25	2093-2100	poultry	abstract[114]|animal[115]	new[114]|new[115]	_	_
15-26	2101-2106	after	abstract[114]|animal[115]	new[114]|new[115]	_	_
15-27	2107-2116	infection	abstract[114]|animal[115]|event	new[114]|new[115]|giv	coref	17-1[134_0]
15-28	2117-2118	.	_	_	_	_

#Text=Viruses that cause immunosuppression in chickens include Marek ’s disease virus ( MDV ) , reticuloendotheliosis virus ( REV ) , avian leukosis virus ( ALV ) , infectious bursal disease virus ( IBDV ) , chicken infectious anemia virus ( CIAV ) and avian reovirus ( ARV ) .
16-1	2119-2126	Viruses	abstract	giv	coref	17-6[136_0]
16-2	2127-2131	that	_	_	_	_
16-3	2132-2137	cause	_	_	_	_
16-4	2138-2155	immunosuppression	abstract	new	coref	18-28
16-5	2156-2158	in	_	_	_	_
16-6	2159-2167	chickens	animal	new	coref	17-4[135_0]
16-7	2168-2175	include	_	_	_	_
16-8	2176-2181	Marek	person[120]|abstract[121]	new[120]|giv[121]	appos|appos	16-13[0_121]|16-13[0_121]
16-9	2182-2184	’s	person[120]|abstract[121]	new[120]|giv[121]	_	_
16-10	2185-2192	disease	abstract[121]	giv[121]	_	_
16-11	2193-2198	virus	abstract[121]	giv[121]	_	_
16-12	2199-2200	(	_	_	_	_
16-13	2201-2204	MDV	abstract	giv	coref	16-16[123_0]
16-14	2205-2206	)	_	_	_	_
16-15	2207-2208	,	_	_	_	_
16-16	2209-2230	reticuloendotheliosis	abstract[123]	giv[123]	appos	16-19[0_123]
16-17	2231-2236	virus	abstract[123]	giv[123]	_	_
16-18	2237-2238	(	_	_	_	_
16-19	2239-2242	REV	abstract	giv	coref	16-29[127_0]
16-20	2243-2244	)	_	_	_	_
16-21	2245-2246	,	_	_	_	_
16-22	2247-2252	avian	_	_	_	_
16-23	2253-2261	leukosis	_	_	_	_
16-24	2262-2267	virus	_	_	_	_
16-25	2268-2269	(	_	_	_	_
16-26	2270-2273	ALV	abstract	new	_	_
16-27	2274-2275	)	_	_	_	_
16-28	2276-2277	,	_	_	_	_
16-29	2278-2288	infectious	abstract[127]	giv[127]	appos	16-34[0_127]
16-30	2289-2295	bursal	event|abstract[127]	new|giv[127]	_	_
16-31	2296-2303	disease	abstract[127]	giv[127]	_	_
16-32	2304-2309	virus	abstract[127]	giv[127]	_	_
16-33	2310-2311	(	_	_	_	_
16-34	2312-2316	IBDV	abstract	giv	coref	16-37[130_0]
16-35	2317-2318	)	_	_	_	_
16-36	2319-2320	,	_	_	_	_
16-37	2321-2328	chicken	animal|abstract[130]	new|giv[130]	_	_
16-38	2329-2339	infectious	abstract[130]	giv[130]	_	_
16-39	2340-2346	anemia	abstract[130]	giv[130]	_	_
16-40	2347-2352	virus	abstract[130]	giv[130]	_	_
16-41	2353-2354	(	_	_	_	_
16-42	2355-2359	CIAV	organization	new	_	_
16-43	2360-2361	)	_	_	_	_
16-44	2362-2365	and	_	_	_	_
16-45	2366-2371	avian	person	new	_	_
16-46	2372-2380	reovirus	_	_	_	_
16-47	2381-2382	(	_	_	_	_
16-48	2383-2386	ARV	abstract	new	_	_
16-49	2387-2388	)	_	_	_	_
16-50	2389-2390	.	_	_	_	_

#Text=The infection of chickens with these viruses not only causes death , but also increases susceptibility to other microbial infections and the risk of failure in subsequent vaccination against other diseases , leading to serious economic losses .
17-1	2391-2394	The	event[134]	giv[134]	_	_
17-2	2395-2404	infection	event[134]	giv[134]	_	_
17-3	2405-2407	of	event[134]	giv[134]	_	_
17-4	2408-2416	chickens	event[134]|animal[135]	giv[134]|giv[135]	coref	18-19[149_135]
17-5	2417-2421	with	event[134]|animal[135]	giv[134]|giv[135]	_	_
17-6	2422-2427	these	event[134]|animal[135]|abstract[136]	giv[134]|giv[135]|giv[136]	_	_
17-7	2428-2435	viruses	event[134]|animal[135]|abstract[136]	giv[134]|giv[135]|giv[136]	_	_
17-8	2436-2439	not	_	_	_	_
17-9	2440-2444	only	_	_	_	_
17-10	2445-2451	causes	_	_	_	_
17-11	2452-2457	death	event	giv	_	_
17-12	2458-2459	,	_	_	_	_
17-13	2460-2463	but	_	_	_	_
17-14	2464-2468	also	_	_	_	_
17-15	2469-2478	increases	_	_	_	_
17-16	2479-2493	susceptibility	abstract[138]	new[138]	_	_
17-17	2494-2496	to	abstract[138]	new[138]	_	_
17-18	2497-2502	other	abstract[138]|abstract[139]	new[138]|new[139]	_	_
17-19	2503-2512	microbial	abstract[138]|abstract[139]	new[138]|new[139]	_	_
17-20	2513-2523	infections	abstract[138]|abstract[139]	new[138]|new[139]	_	_
17-21	2524-2527	and	abstract[138]	new[138]	_	_
17-22	2528-2531	the	abstract[138]|abstract[140]	new[138]|new[140]	ana	18-1[0_140]
17-23	2532-2536	risk	abstract[138]|abstract[140]	new[138]|new[140]	_	_
17-24	2537-2539	of	abstract[138]|abstract[140]	new[138]|new[140]	_	_
17-25	2540-2547	failure	abstract[138]|abstract[140]|event[141]	new[138]|new[140]|new[141]	_	_
17-26	2548-2550	in	abstract[138]|abstract[140]|event[141]	new[138]|new[140]|new[141]	_	_
17-27	2551-2561	subsequent	abstract[138]|abstract[140]|event[141]|event[142]	new[138]|new[140]|new[141]|new[142]	_	_
17-28	2562-2573	vaccination	abstract[138]|abstract[140]|event[141]|event[142]	new[138]|new[140]|new[141]|new[142]	_	_
17-29	2574-2581	against	abstract[138]|abstract[140]|event[141]|event[142]	new[138]|new[140]|new[141]|new[142]	_	_
17-30	2582-2587	other	abstract[138]|abstract[140]|event[141]|event[142]|abstract[143]	new[138]|new[140]|new[141]|new[142]|giv[143]	coref	18-21[150_143]
17-31	2588-2596	diseases	abstract[138]|abstract[140]|event[141]|event[142]|abstract[143]	new[138]|new[140]|new[141]|new[142]|giv[143]	_	_
17-32	2597-2598	,	_	_	_	_
17-33	2599-2606	leading	_	_	_	_
17-34	2607-2609	to	_	_	_	_
17-35	2610-2617	serious	abstract[144]	new[144]	_	_
17-36	2618-2626	economic	abstract[144]	new[144]	_	_
17-37	2627-2633	losses	abstract[144]	new[144]	_	_
17-38	2634-2635	.	_	_	_	_

#Text=It has been reported that miRNAs are involved in a number of regulatory activities in the response of chickens with avian immunosuppressive diseases , including tumorigenesis , immunosuppression , cell proliferation and viral replication .
18-1	2636-2638	It	abstract	giv	_	_
18-2	2639-2642	has	_	_	_	_
18-3	2643-2647	been	_	_	_	_
18-4	2648-2656	reported	_	_	_	_
18-5	2657-2661	that	_	_	_	_
18-6	2662-2668	miRNAs	abstract	giv	coref	19-8
18-7	2669-2672	are	_	_	_	_
18-8	2673-2681	involved	_	_	_	_
18-9	2682-2684	in	_	_	_	_
18-10	2685-2686	a	abstract[147]	new[147]	_	_
18-11	2687-2693	number	abstract[147]	new[147]	_	_
18-12	2694-2696	of	abstract[147]	new[147]	_	_
18-13	2697-2707	regulatory	abstract[147]	new[147]	_	_
18-14	2708-2718	activities	abstract[147]	new[147]	_	_
18-15	2719-2721	in	_	_	_	_
18-16	2722-2725	the	abstract[148]	new[148]	_	_
18-17	2726-2734	response	abstract[148]	new[148]	_	_
18-18	2735-2737	of	abstract[148]	new[148]	_	_
18-19	2738-2746	chickens	abstract[148]|animal[149]	new[148]|giv[149]	_	_
18-20	2747-2751	with	abstract[148]|animal[149]	new[148]|giv[149]	_	_
18-21	2752-2757	avian	abstract[148]|animal[149]|abstract[150]	new[148]|giv[149]|giv[150]	coref	19-15[161_150]
18-22	2758-2775	immunosuppressive	abstract[148]|animal[149]|abstract[150]	new[148]|giv[149]|giv[150]	_	_
18-23	2776-2784	diseases	abstract[148]|animal[149]|abstract[150]	new[148]|giv[149]|giv[150]	_	_
18-24	2785-2786	,	abstract[148]|animal[149]|abstract[150]	new[148]|giv[149]|giv[150]	_	_
18-25	2787-2796	including	abstract[148]|animal[149]|abstract[150]	new[148]|giv[149]|giv[150]	_	_
18-26	2797-2810	tumorigenesis	abstract[148]|animal[149]|abstract[150]|event	new[148]|giv[149]|giv[150]|giv	_	_
18-27	2811-2812	,	abstract[148]|animal[149]|abstract[150]	new[148]|giv[149]|giv[150]	_	_
18-28	2813-2830	immunosuppression	abstract[148]|animal[149]|abstract[150]|abstract	new[148]|giv[149]|giv[150]|giv	_	_
18-29	2831-2832	,	abstract[148]|animal[149]|abstract[150]	new[148]|giv[149]|giv[150]	_	_
18-30	2833-2837	cell	abstract[148]|animal[149]|abstract[150]|place|abstract[154]	new[148]|giv[149]|giv[150]|giv|giv[154]	_	_
18-31	2838-2851	proliferation	abstract[148]|animal[149]|abstract[150]|abstract[154]	new[148]|giv[149]|giv[150]|giv[154]	_	_
18-32	2852-2855	and	abstract[148]|animal[149]|abstract[150]	new[148]|giv[149]|giv[150]	_	_
18-33	2856-2861	viral	abstract[148]|animal[149]|abstract[150]|abstract[155]	new[148]|giv[149]|giv[150]|new[155]	_	_
18-34	2862-2873	replication	abstract[148]|animal[149]|abstract[150]|abstract[155]	new[148]|giv[149]|giv[150]|new[155]	_	_
18-35	2874-2875	.	_	_	_	_

#Text=In this review , the roles of miRNAs in the pathogenesis and control of different avian immunosuppressive diseases will be discussed , which may provide some clues to further understandings of pathogenesis of avian immunosuppressive diseases .
19-1	2876-2878	In	_	_	_	_
19-2	2879-2883	this	abstract[156]	new[156]	_	_
19-3	2884-2890	review	abstract[156]	new[156]	_	_
19-4	2891-2892	,	_	_	_	_
19-5	2893-2896	the	abstract[157]	new[157]	_	_
19-6	2897-2902	roles	abstract[157]	new[157]	_	_
19-7	2903-2905	of	abstract[157]	new[157]	_	_
19-8	2906-2912	miRNAs	abstract[157]|object	new[157]|giv	_	_
19-9	2913-2915	in	abstract[157]	new[157]	_	_
19-10	2916-2919	the	abstract[157]|abstract[159]	new[157]|new[159]	coref	19-32[164_159]
19-11	2920-2932	pathogenesis	abstract[157]|abstract[159]	new[157]|new[159]	_	_
19-12	2933-2936	and	abstract[157]	new[157]	_	_
19-13	2937-2944	control	abstract[157]|abstract[160]	new[157]|new[160]	_	_
19-14	2945-2947	of	abstract[157]|abstract[160]	new[157]|new[160]	_	_
19-15	2948-2957	different	abstract[157]|abstract[160]|abstract[161]	new[157]|new[160]|giv[161]	coref	19-34[165_161]
19-16	2958-2963	avian	abstract[157]|abstract[160]|abstract[161]	new[157]|new[160]|giv[161]	_	_
19-17	2964-2981	immunosuppressive	abstract[157]|abstract[160]|abstract[161]	new[157]|new[160]|giv[161]	_	_
19-18	2982-2990	diseases	abstract[157]|abstract[160]|abstract[161]	new[157]|new[160]|giv[161]	_	_
19-19	2991-2995	will	_	_	_	_
19-20	2996-2998	be	_	_	_	_
19-21	2999-3008	discussed	_	_	_	_
19-22	3009-3010	,	_	_	_	_
19-23	3011-3016	which	_	_	_	_
19-24	3017-3020	may	_	_	_	_
19-25	3021-3028	provide	_	_	_	_
19-26	3029-3033	some	abstract[162]	new[162]	_	_
19-27	3034-3039	clues	abstract[162]	new[162]	_	_
19-28	3040-3042	to	abstract[162]	new[162]	_	_
19-29	3043-3050	further	abstract[162]|abstract[163]	new[162]|new[163]	_	_
19-30	3051-3065	understandings	abstract[162]|abstract[163]	new[162]|new[163]	_	_
19-31	3066-3068	of	abstract[162]|abstract[163]	new[162]|new[163]	_	_
19-32	3069-3081	pathogenesis	abstract[162]|abstract[163]|abstract[164]	new[162]|new[163]|giv[164]	_	_
19-33	3082-3084	of	abstract[162]|abstract[163]|abstract[164]	new[162]|new[163]|giv[164]	_	_
19-34	3085-3090	avian	abstract[162]|abstract[163]|abstract[164]|abstract[165]	new[162]|new[163]|giv[164]|giv[165]	_	_
19-35	3091-3108	immunosuppressive	abstract[162]|abstract[163]|abstract[164]|abstract[165]	new[162]|new[163]|giv[164]|giv[165]	_	_
19-36	3109-3117	diseases	abstract[162]|abstract[163]|abstract[164]|abstract[165]	new[162]|new[163]|giv[164]|giv[165]	_	_
19-37	3118-3119	.	_	_	_	_
